Evidence map›Paper›PMID 27471667›Full record

ReviewActa pharmaceutica Sinica. B2016

Charge-reversal nanoparticles: novel targeted drug delivery carriers.

Xinli Chen, Lisha Liu, Chen Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  9. Article
  10. Review
  11. Nanovaccines empowering CD8Theranostics · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. [Targeted killing of CD133Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinli ChenKey Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Lisha LiuKey Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Chen JiangKey Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China; State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spurred by significant progress in materials chemistry and drug delivery, charge-reversal nanocarriers are being developed to deliver anticancer formulations in spatial-, temporal- and dosage-controlled approaches. Charge-reversal nanoparticles can release their drug payload in response to specific stimuli that alter the charge on their surface. They can elude clearance from the circulation and be activated by protonation, enzymatic cleavage, or a molecular conformational change. In this review, we discuss the physiological basis for, and recent advances in the design of charge-reversal nanoparticles that are able to control drug biodistribution in response to specific stimuli, endogenous factors (changes in pH, redox gradients, or enzyme concentration) or exogenous factors (light or thermos-stimulation).

Indexed as

Abs, integrin aVb3 mAbsB-PDEAEA, poly[(2-acryloyl) ethyl (p-boronic acid benzyl) diethylammonium bromide]BPS, bridged polysilsesquioxanexerogelBSA, bovine serum albuminCA4, combretastatin A4Cancer therapyCAPL, charge reversible pullulan-basedCharge-reversal nanoparticlesCHPNH2, cationic cholesteryl group–bearing pullulansCit, citraconic anhydrideCMC, carboxymethyl celluloseCPLAs, cationic polylactidesCya, cysteamine hydrochlorideDAP, 2,3-diamino-propionateDCL, dimethyl maleamidic acid-ε-caprolactoneDDS, drug delivery systemDMA, 2,3-dimethylmaleic anhydrideDM, dimyristeroylDMPA, dimethylol propionic acidDOX, doxorubicinDrug delivery carriersFITC, fluorescein isothiocyanateGlu, glutamic acidGO, graphene oxideGSH, glutathioneHCC, hepatocellular carcinomaHEP, 1,4-bis(2-hydroxyethyl) piperazineHis, histidineHMP, p-hydroxylmethylenephenolMG, microgelsMMPs, matrix metalloproteinasesMNP, magnetic nanoparticlesNanotechnologyNPs, nanoparticlesPAEP, poly(allyl ethylene phosphate)pA-F, fluorescein-labeled polyanionPAH, poly(allylamine) hydrochloridePBAE, poly(β-amino ester)PCL, poly(ε-caprolactone)PDADMAC, poly(diallyldimethylammonium chloride)PEG, polyethylene glycolPEI, polyethyleniminePEO, poly(ethylene oxide)PK, protein kinasePLA, ploylactic acidPLGA, poly(lactic-co-glycolic acid)PLL, poly(l-lysine)PMA, poly(methacrylic acid)PS, pH sensitivePSS, poly(sodium 4-styrenesulfonate)PSSS, poly(styrene-co-4-styrene-sulfonate)PTX, paclitaxelPU, polyurethanePVPON, poly(N-vinylpyrrolidone)ROS, reactive oxygen speciesSOD, superoxide dismutaseStimuli responsiveTMA, 2-(mercaptoethyl) trimethylammonium chlorideTUNA, thioundecyl-tetraethyleneglycolester-o-nitrobenzy-lethyldimethyl ammonium bromide

Identifiers

PMID27471667
PMCPMC4951588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.